Eric Cornut will join the Board of Helsinn Group as a Non-Executive Director at Helsinn, Swiss pharmaceutical Group focused on building quality cancer care products.
Cornut said: “I have watched Helsinn closely throughout my career and have always been impressed how this private, family business has continued to grow, and is now an international pharmaceutical company, whilst always retaining the values of integrity, respect and quality.”
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, said: “At the same time as welcoming a new member of the Board, I would like to thank Franco De Vecchi for his many years of hard work and expert guidance.”
Cornut has more than 25 years of pharmaceutical management experience and was Interim Director General of The European Federation of Pharmaceutical Industries and Associations (EFPIA), where previously he was Chair of EFPIA's executive committee for five years (2008-2013). He is currently a Member of the Supervisory Board at Stada.
Prior to this, Cornut spent more than 20 years at Novartis where he concluded his career as Chief Ethics, Compliance and Policy Officer of Novartis where he led the Integrity and Compliance, as well as the Public Affairs functions, at the same time as serving as the Chair of Novartis Group Japan.
Previously, Cornut served as Chief Commercial Officer of Novartis Pharmaceuticals where he was responsible for Global Product Strategy and Commercialisation including Medical Affairs, Pricing and Market Access, Health Economics and Outcomes Research as well as Business Development and Licensing.
In this role, Cornut transformed the organisation to be more patient-centric. Between 2007–2012, he led Pharma Region Europe for six years where he oversaw the operations of 35 countries with approximately 9,000 associates.
Under Cornut's leadership, his teams successfully launched 13 new products and achieved more than $7bn in sales.
Cornut has a Doctoral degree in Law from the University of Basel, Switzerland, and a Master of Law degree from the University of California, Berkeley, in the United States.